18-fluorodeoxy-glucose Positron Emission Computed Tomography As Predictive of Response After Chemoradiation in Oesophageal Cancer Patients
Overview
Authors
Affiliations
Introduction: The purpose of this study was to evaluate if a baseline, an interim or a post-chemoradiation (CTRT) 18-fluorodeoxy-glucose positron emission computed tomography (18F-FDG PET/CT) studies could provide information on pathologic response to CTRT and overall survival (OS).
Materials And Methods: Thirty-one patients with histologically proven adenocarcinoma or squamous cell carcinoma of the oesophagus, fit for trimodality therapy were prospectively enrolled. Most were men (93.5%), and had a stage III cancer (74.2%). Chemotherapy consisted of oxaliplatin/5-fluorouracil (45.2%) and taxane/5-fluorouracil (54.8%). All patients underwent a baseline, an interim (performed 12 ± 2 days after the onset of CTRT) and a post-CTRT 18F-FDG PET/CT study. The 18F-FDG PET/CT variables evaluated were at baseline, interim and post-CTRT studies maximum standardised uptake value (SUV max) and total lesion glycolysis (TLG). Clinical and 18F-FDG PET/CT parameters were correlated with pathologic complete response (pathCR) and OS.
Results: Among the 31 patients studied, 61.3% achieved a clinical complete response (cCR) and 87.1% had surgery. The median OS was 35.1 months (95% confidence interval (CI): 19.9-NA). PathCR rate was 22.2%. There was only a marginal association between cCR and pathCR (p = 0.06). None of the other variables was predictive of pathCR. There was association between OS and baseline TLG (p = 0.03) at the optimal cutoff TLG value of 75.15. Additionally, TLG and ΔTLG post-CTRT were also associated with OS (p = 0.01 and 0.03, respectively).
Conclusion: None of the PET parameters is predictive of pathCR but TLG at baseline and post-CTRT are prognostic of OS.
Zeng Y, Liu Y, Li J, Feng B, Lu J Ann Surg Oncol. 2024; 32(3):1635-1650.
PMID: 39586955 DOI: 10.1245/s10434-024-16568-z.
The prognostic value of pretreatment [F]FDG PET/CT parameters in esophageal cancer: a meta-analysis.
Huang M, Wang W, Wang R, Tian R Eur Radiol. 2024; .
PMID: 39570366 DOI: 10.1007/s00330-024-11207-3.
Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future.
Liu Y World J Gastroenterol. 2023; 29(34):5020-5037.
PMID: 37753366 PMC: 10518742. DOI: 10.3748/wjg.v29.i34.5020.
Zhu H, Hao S, Tseng I, Shen J, Rivin Del Campo E, Davies A Quant Imaging Med Surg. 2023; 13(9):6280-6295.
PMID: 37711778 PMC: 10498200. DOI: 10.21037/qims-22-1306.
Withey S, Owczarczyk K, Grzeda M, Yip C, Deere H, Green M Eur J Surg Oncol. 2023; 49(10):106934.
PMID: 37183047 PMC: 10769883. DOI: 10.1016/j.ejso.2023.05.009.